+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 16 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are investigating whether adding the drug Docetaxel to the usual hormone treatments, Androgen Deprivation Therapy ADT and Androgen-Receptor Pathway Inhibitor ARPI, can better control metastatic castration sensitive prostate cancer in men who have not responded optimally to initial hormone therapy. This phase III, international, open-label, randomized trial seeks to compare the effectiveness of this combined approach against the standard hormone therapy alone. Participants will be randomly assigned to receive either the standard hormone therapy with ADT plus ARPI or the same hormone therapy combined with Docetaxel chemotherapy. The trial focuses on men with metastatic prostate cancer who continue to have elevated PSA levels after 6 to 12 months of hormone-targeting treatment. Treatments are administered according to physician choice and assignment, and the study evaluates outcomes over a long period. During the trial, participants will be closely monitored with assessments including PSA levels and clinical progression over 39 months. Researchers will measure overall survival as the primary outcome, along with secondary outcomes such as PSA progression, PSA response, PSA kinetics, and progression-free survival. Participants must be accessible for treatment and follow-up to allow for complete documentation of treatment effects and adverse events throughout the study duration.

Age: 18Years +MALEPhase 3
395 locations
E

Actively Recruiting

Researchers are studying younger breast cancer survivors who experience elevated depressive symptoms to compare digital mindfulness meditation programs. This phase III clinical trial evaluates two digital methods a live instructor-led program over Zoom and a self-paced app-based program. The study aims to find which digital approach best improves mental health and well-being after completing primary cancer treatment. Participants are randomly assigned to one of three groups a live online mindfulness group meeting weekly for six weeks via Zoom a self-paced app-based mindfulness program with lessons and exercises unlocked sequentially or a meditation-only control group using guided audio meditations. All participants will have access to the mindfulness meditation app throughout the study, including six months of follow-up. Devices and internet access are provided to those who need them. During the study, participants will attend group sessions or use the app according to their assigned group and complete daily mindfulness practice. Researchers will track engagement and measure depressive symptoms at two weeks, three to six months, and six months after the intervention. They will also assess fatigue and explore factors influencing treatment effects and cost-effectiveness. The total study duration spans the six-week intervention plus six months of follow-up.

Age: 18Years - 50YearsAll GendersPhase 3
456 locations
A

Actively Recruiting

Healthy Volunteer

Researchers are evaluating an online educational program called Current Together After Cancer CTAC to see if it helps colorectal cancer survivors who had surgery receive follow-up care that matches current guidelines. This phase III trial focuses on patients with stage II or III colorectal cancer who have had their tumors surgically removed. The study aims to improve patients knowledge about surveillance, their confidence in managing follow-up care, and satisfaction with the involvement of a supporter in their care. Patients in the trial are randomly assigned to one of two groups. One group and their supporter get access to the CTAC intervention website, which contains educational content and interactive modules related to colorectal cancer surveillance. The other group and their supporter receive access to a general health education website. Participants may review their assigned website as often as they like for up to 16 months. During the study, participants will complete questionnaires at baseline, 3 months, and 16 months to assess knowledge, self-efficacy, cancer worry, preferences, and satisfaction with supporter engagement. Researchers will measure whether patients receive colorectal cancer surveillance aligned with guidelines at 16 months. The study also explores how supporters participation relates to patient outcomes. Participants may be contacted via email or phone for study activities and are encouraged to complete all scheduled assessments.

Age: 18Years +All GendersPhase 3
384 locations
C

Actively Recruiting

Researchers are comparing two chemotherapy regimens, mFOLFIRINOX and mFOLFOX, both with or without the immunotherapy drug nivolumab, for treating patients with advanced, unresectable, or metastatic HER2-negative adenocarcinoma of the esophagus, gastroesophageal junction, or stomach. This phase III trial aims to see if mFOLFIRINOX with or without nivolumab improves overall survival compared to mFOLFOX with or without nivolumab. The study also evaluates treatment safety, response rates, and explores biomarkers like PD-L1 combined positive score and cell-free DNA. Participants randomized to one of two groups will receive intravenous chemotherapy every 14 days in cycles up to 12 times. One group receives fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan, with nivolumab given as clinically indicated. The other group receives fluorouracil, leucovorin calcium, and oxaliplatin, also with nivolumab as needed. Throughout the study, patients undergo MRI and CT scans and may have blood samples collected. Nivolumab administration depends on clinical need. During the trial, participants will have regular imaging to monitor tumor status and blood tests to track biomarkers. Patient-reported outcomes on treatment side effects are collected at baseline and during cycles. After treatment, participants are followed every six months for up to three years or until tumor progression or withdrawal. The main outcome measured is overall survival over two years, with additional assessments of progression-free survival, response duration, and safety up to three years.

Age: 18Years +All GendersPhase 3
802 locations
M

Actively Recruiting

Researchers are evaluating a Master Screening and Reassessment Protocol MSRP to improve the matching of patients with myeloid cancers, such as acute myeloid leukemia AML or myelodysplastic syndrome MDS, to appropriate clinical trials or standard treatments. This study focuses on using bone marrow and blood tests to detect biomarkers that guide treatment decisions, aiming to assign participants quickly to targeted treatment studies or standard care pathways. The study also assesses the ability to organize and process data rapidly to support treatment assignments. Participants undergo bone marrow aspiration and blood collection for rapid genetic testing to identify mutations that may be targeted by specific therapies within various substudies. If no targetable mutation is found, participants may be assigned to novel combination drug studies or continue standard of care through the Tier Advancement Pathway TAP. Treatments studied include various drug regimens involving agents such as azacitidine, venetoclax, cytarabine, daunorubicin, and others, administered intravenously, subcutaneously, or orally according to specific schedules. Some participants may also receive hematopoietic stem cell transplantation with conditioning regimens. Treatment cycles vary in length and number depending on the assigned substudy. Throughout the study, participants have multiple bone marrow aspirations, biopsies, blood sample collections, and imaging tests such as echocardiography or MUGA scans for monitoring. Researchers assess timing for treatment assignment, response rates, adverse events, and overall survival among other outcomes. The study includes ongoing reassessment to allow movement to higher tier treatment options when appropriate. Participation may last for extended periods, with some regimens continuing up to two years or more, depending on response and disease progression.

Age: 18Years +All GendersPhase 2
360 locations
R

Actively Recruiting

Researchers are evaluating whether adding targeted radiotherapy can reduce the chance of lung cancer growing or spreading compared to the usual drug combination treatment for metastatic non-small cell lung cancer NSCLC. This Phase 3 trial focuses on patients whose disease has worsened and explores if this new approach is better or worse than standard care. The study involves patients with stage IV NSCLC without actionable driver mutations, who have experienced limited progression on first-line immunotherapy or chemotherapy. Participants are randomly assigned to one of two groups one group receives stereotactic body radiotherapy SBRT followed by standard therapy, while the other group receives systemic therapy chosen by their doctor without SBRT. SBRT must be started within 3 weeks of enrollment for those in the radiotherapy group. Treatments follow current NSCLC guidelines and consider prior therapies and patient safety, including assessments by radiation oncologists. During the study, participants undergo regular evaluations including imaging to monitor tumor progression, safety assessments, and quality of life questionnaires. Researchers will measure progression-free survival and overall survival over 5.5 years, alongside tracking adverse events and patient-reported outcomes. Participants must be able to complete questionnaires in English, French, or Spanish and remain available for treatment and follow-up throughout the study duration.

Age: 18Years +All GendersPhase 3
75 locations
S

Actively Recruiting

Researchers are evaluating whether 6 months of HER2-targeted therapy is as effective as 12 months for treating early-stage HER2-positive breast cancer in patients who have no remaining invasive cancer after preoperative chemotherapy with trastuzumab. The study aims to compare recurrence-free survival and quality of life between shorter and longer treatment durations. Secondary goals include assessing serious side effects, overall survival, local cancer recurrence, and patient-reported symptoms. Participants are randomly assigned to either 6 months or 12 months of HER2-targeted therapy using trastuzumab and possibly pertuzumab, given intravenously or subcutaneously every 21 days. Treatment continues up to 9 or 17 cycles unless disease progresses or side effects are unacceptable. During the trial, participants undergo heart function tests ECHO or MUGA, imaging such as mammography, ultrasound, or MRI, and may provide blood and tissue samples for research. After treatment, participants are followed every 6 months for 5 years or until cancer recurrence, then annually up to 10 years. Researchers monitor recurrence-free survival and quality of life using validated questionnaires. Safety is closely tracked through adverse event reporting, and long-term outcomes including overall survival and brain metastasis occurrence are assessed to understand treatment impact.

Age: 18Years +All GendersPhase 3
702 locations
R

Actively Recruiting

This trial investigates treatment options for patients with differentiated thyroid cancer that does not respond to usual therapies and has a specific mutation called BRAF V600E. The study aims to compare the effects of cabozantinib alone versus a combination of dabrafenib and trametinib in patients whose cancer has progressed after prior treatments. Researchers want to find out which treatment may control cancer growth longer and assess differences in safety and quality of life. Participants are randomly assigned to one of two groups. One group receives dabrafenib twice daily and trametinib once daily in 28-day cycles, while the other group takes cabozantinib once daily in 28-day cycles. Both groups undergo CT scans, blood tests, and may have MRI scans during treatment. If the cancer progresses, participants may switch to the other treatment group. Throughout the study, participants are monitored for cancer progression, response to treatment, overall survival, and side effects. Quality of life is assessed using patient questionnaires. After treatment ends, follow-up visits occur every three months for two years, then every six months up to five years to continue monitoring health and outcomes.

Age: 18Years +All GendersPhase 3
307 locations
C

Actively Recruiting

Researchers are studying newly diagnosed patients with IDH wildtype, MGMT-unmethylated glioblastoma to compare two types of radiation therapy combined with temozolomide chemotherapy. This phase III trial focuses on whether temporally-modulated pulsed radiation therapy TMPRT alongside temozolomide can better preserve memory and thinking functions and improve survival compared to standard radiation therapy with temozolomide. The study also addresses the challenges of treating MGMT-unmethylated tumors, which often respond less to chemotherapy alone. Participants are randomly assigned to one of two groups. The first group receives standard radiation therapy daily over 12-15 minutes for 3 or 6 weeks, along with daily oral temozolomide for 21 or 42 days, followed by additional temozolomide cycles every 28 days for six cycles. The second group receives TMPRT delivered in 10-13 pulses with 3-minute breaks over 30-40 minutes each session, also 5 days a week for 3 or 6 weeks, combined with the same temozolomide schedule as the first group. After radiation, both groups continue temozolomide in cycles. Throughout the trial, participants undergo CT or MRI scans and may provide optional blood samples. During the study, participants complete neurocognitive testing to track memory and thinking abilities, quality of life questionnaires, and assessments of frailty. Researchers monitor overall survival, progression-free survival, and adverse events up to 9 months after radiation therapy. Follow-up visits occur at months 1, 3, 5, 7, 9, and 12, then annually for 4 years. Blood samples are collected for future research, and imaging is used to evaluate brain changes. The trial lasts several years, with careful monitoring to evaluate the impact of the different radiation therapies combined with temozolomide.

Age: 18Years +All GendersPhase 3
54 locations
P

Actively Recruiting

Researchers are evaluating vorasidenib combined with temozolomide compared to temozolomide alone in patients newly diagnosed with grade 3 IDH-mutant astrocytoma after radiation therapy. This phase III trial aims to see if adding vorasidenib improves progression-free survival and overall treatment outcomes. The study also assesses safety, response rates, and quality of life measures in this patient group. Participants receive radiation therapy daily Monday through Friday for 33 sessions using methods like intensity-modulated radiation therapy or proton therapy. Four weeks after radiation, patients start 28-day treatment cycles with temozolomide given orally on days 1 to 5, combined with either vorasidenib or a placebo taken daily for 28 days. This treatment repeats up to 12 months unless disease progression or unacceptable side effects occur. Throughout the study, patients undergo regular MRI scans and blood sample collections. After completing treatment, follow-up occurs every three months for two years, then every four months for another two years, and every six months up to 10 years. Researchers will measure progression-free survival, overall survival, tumor response, time to next treatment, symptom burden, and quality of life over this period.

Age: 12Years +All GendersPhase 3
177 locations

1-10 of 16

1